Table 4.
Results of univariate Cox proportional hazard analysis for the association among baseline variables, and treatment, and the risk of reaching the all‐cause treatment failure endpoint (n = 151 cats)
| Variable | Hazard ratio | 95% confidence interval | P value | |
|---|---|---|---|---|
| Lower limit | Upper limit | |||
| Treatment (benazepril versus placebo) | 1.23 | 0.75 | 2.02 | .42 |
| Age (years) | 1.05 | 0.99 | 1.12 | .08 |
| Sex (male versus female) | 1.22 | 0.65 | 2.24 | .53 |
| Congenital disorder (versus acquired) | 0.83 | 0.38 | 1.83 | .65 |
| Fractional shortening (%) | 0.97 | 0.95 | 0.99 | <.001 |
| LA diameter (short axis view, mm) | 1.13 | 1.08 | 1.18 | <.001 |
| End diastolic LV diameter (M‐mode, mm) | 1.00 | 0.98 | 1.02 | .76 |
| End diastolic LV free wall thickness (M‐mode, mm) | 0.82 | 0.70 | 0.96 | .02 |
| End diastolic LV septum thickness (M‐mode, mm) | 0.76 | 0.63 | 0.91 | .003 |
| Hematocrit (%) | 0.96 | 0.93 | 1.00 | .05 |
| White blood cells (109/L) | 1.07 | 1.03 | 1.11 | <.001 |
| Plasma albumin (g/L) | 0.94 | 0.87 | 1.02 | .11 |
| Plasma calcium (mmol/L) | 1.17 | 0.31 | 4.47 | .82 |
| Plasma creatinine (μmol/L) | 1.01 | 1.00 | 1.01 | .004 |
| Plasma phosphate (mmol/L) | 1.10 | 0.62 | 1.95 | .76 |
| Plasma potassium (mmol/L) | 1.14 | 0.91 | 1.44 | .25 |
| Plasma sodium (mmol/L) | 0.98 | 0.93 | 1.05 | .60 |
| Plasma urea (g/L) | 3.06 | 1.64 | 5.72 | <.001 |
| Plasma alkaline phosphatase (U/L) | 0.99 | 0.98 | 1.01 | .33 |
| CHF signs present (versus absent) | 3.77 | 2.00 | 7.11 | <.001 |
| Arrhythmia present (versus absent) | 2.78 | 1.55 | 4.99 | <.001 |
| Gallop sound present (versus absent) | 1.69 | 0.97 | 2.97 | .07 |
| Level of activity reduced (versus not reduced) | 3.85 | 1.21 | 12.29 | .02 |
| Quality of life poor (versus good) | 2.37 | 1.44 | 3.91 | <.001 |
Notes: P values <.05 are shown in bold. Variables were analyzed as continuous unless stated.
Abbreviations: CHF, congestive heart failure; LA, left atrium; LV, left ventricle.